Trial Profile

Pivotal study of Glecirasib in combination with an anti-EGFR antibody cetuximab in patients with colorectal cancer

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 03 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cetuximab (Primary) ; Glecirasib (Primary)
Indications Colorectal cancer
Focus Adverse reactions; Registrational; Therapeutic Use
Sponsors Jacobio Pharmaceuticals

Most Recent Events

28 Mar 2024 According to a Jacobio Pharma media release, this Phase III pivotal trial design of glecirasib monotherapy or glecirasib in combination with cetuximab is expected to be approved by CDE in Q2 2024.
30 Aug 2023 According to Jacobio media release, trial is currently being discussed with the Centre for Drug Evaluation (CDE).
14 Apr 2023 According to Jacobio media release, this study is expected to be initiated in Q4 of 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com